{"DataElement":{"publicId":"6180882","version":"1","preferredName":"HPV-Mediated p16-Positive Oropharyngeal Cancer AJCC Edition 8 Clinical Tumor T Category","preferredDefinition":"Extent of the primary p16-positive oropharyngeal carcinoma based on information obtained from the date of cancer diagnosis until the start of definitive treatment, or within four months (whichever is shorter), using AJCC Ed.","longName":"OX16P_AJC8_CLN_T_CAT","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6072205","version":"1","preferredName":"Oropharynx Neoplasm CDKN2A-p16 Positive Clinical T Category","preferredDefinition":"The part of the pharynx between the soft palate and the upper portion of the epiglottis._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._Indicates that CDKN2A-p16 expression has been detected in a sample._Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity._One criteria of the TNM staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","longName":"6052651v1.0:6072203v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6052651","version":"1","preferredName":"Oropharynx Neoplasm","preferredDefinition":"The part of the pharynx between the soft palate and the upper portion of the epiglottis.:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","longName":"C12762:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharynx","conceptCode":"C12762","definition":"The part of the pharynx between the soft palate and the upper portion of the epiglottis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630C1054-6248-5BD4-E053-F662850A4B08","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6072203","version":"1","preferredName":"CDKN2A-p16 Positive Clinical T Category","preferredDefinition":"Indicates that CDKN2A-p16 expression has been detected in a sample.:Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.:One criteria of the TNM staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","longName":"C129258:C25398:C25728","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CDKN2A-p16 Positive","conceptCode":"C129258","definition":"Indicates that CDKN2A-p16 expression has been detected in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Clinical","conceptCode":"C25398","definition":"Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"T Category","conceptCode":"C25728","definition":"One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6541BD54-51B8-7A45-E053-F662850A9C45","latestVersionIndicator":"Yes","beginDate":"2018-02-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-15","modifiedBy":"ONEDATA","dateModified":"2018-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"6541BD54-51C9-7A45-E053-F662850A9C45","latestVersionIndicator":"Yes","beginDate":"2018-02-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-15","modifiedBy":"TAYLORT","dateModified":"2018-04-09","changeDescription":"4/9/18 tt released. 2/15/18 tt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6052783","version":"1","preferredName":"HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma American Joint Committee on Cancer Edition 8 T Category","preferredDefinition":"A finding about one or more characteristics of HPV-mediated (p16-positive) oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system. Oropharyngeal cancers which are p16-negative are staged according to the classification for oropharynx (p16-negative) and hypopharynx cancers. (from AJCC 8th Ed.)_A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._One criteria of the TNM staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion)._A grouping of items based on some commonality or by user defined characteristics.","longName":"6052783v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"2","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"T3","valueDescription":"HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT3 TNM Finding v8","ValueMeaning":{"publicId":"6052787","version":"1","preferredName":"HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT3 TNM Finding v8","longName":"6052787","preferredDefinition":"HPV-mediated (p16-positive) oropharyngeal cancer with tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT3 TNM Finding v8","conceptCode":"C132865","definition":"HPV-mediated (p16-positive) oropharyngeal cancer with tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630F8F5B-03CC-7F30-E053-F662850A8A3D","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630F8F5B-03E5-7F30-E053-F662850A8A3D","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"T4","valueDescription":"HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT4 TNM Finding v8","ValueMeaning":{"publicId":"6052785","version":"1","preferredName":"HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT4 TNM Finding v8","longName":"6052785","preferredDefinition":"HPV-mediated (p16-positive) oropharyngeal cancer with moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible or beyond. Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT4 TNM Finding v8","conceptCode":"C132866","definition":"HPV-mediated (p16-positive) oropharyngeal cancer with moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible or beyond. Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630F8F5B-03A6-7F30-E053-F662850A8A3D","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630F8F5B-03BF-7F30-E053-F662850A8A3D","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"T2","valueDescription":"HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT2 TNM Finding v8","ValueMeaning":{"publicId":"6052789","version":"1","preferredName":"HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT2 TNM Finding v8","longName":"6052789","preferredDefinition":"HPV-mediated (p16-positive) oropharyngeal cancer with tumor larger than 2 cm but not larger than 4 cm in greatest dimension. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT2 TNM Finding v8","conceptCode":"C132864","definition":"HPV-mediated (p16-positive) oropharyngeal cancer with tumor larger than 2 cm but not larger than 4 cm in greatest dimension. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630F8F5B-03F2-7F30-E053-F662850A8A3D","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630F8F5B-040B-7F30-E053-F662850A8A3D","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"T1","valueDescription":"HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT1 TNM Finding v8","ValueMeaning":{"publicId":"6052791","version":"1","preferredName":"HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT1 TNM Finding v8","longName":"6052791","preferredDefinition":"HPV-mediated (p16-positive) oropharyngeal cancer with tumor 2 cm or smaller in greatest dimension. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT1 TNM Finding v8","conceptCode":"C132863","definition":"HPV-mediated (p16-positive) oropharyngeal cancer with tumor 2 cm or smaller in greatest dimension. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630F8F5B-0418-7F30-E053-F662850A8A3D","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630F8F5B-0431-7F30-E053-F662850A8A3D","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"T0","valueDescription":"HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT0 TNM Finding v8","ValueMeaning":{"publicId":"6052793","version":"1","preferredName":"HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT0 TNM Finding v8","longName":"6052793","preferredDefinition":"No primary identified. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT0 TNM Finding v8","conceptCode":"C132862","definition":"No primary identified. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630F8F5B-043E-7F30-E053-F662850A8A3D","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630F8F5B-0457-7F30-E053-F662850A8A3D","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6052782","version":"1","preferredName":"HPV-Mediated (p16-Positive) Oropharyngeal Cancer TNM Finding v8 American Joint Committee on Cancer T Category Category","preferredDefinition":"A finding about one or more characteristics of HPV-mediated (p16-positive) oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system. Oropharyngeal cancers which are p16-negative are staged according to the classification for oropharynx (p16-negative) and hypopharynx cancers. (from AJCC 8th Ed.):A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.:One criteria of the TNM staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).:A grouping of items based on some commonality or by user defined characteristics.","longName":"C132858:C39315:C25728:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HPV-Mediated (p16-Positive) Oropharyngeal Cancer TNM Finding v8","conceptCode":"C132858","definition":"A finding about one or more characteristics of HPV-mediated (p16-positive) oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system. Oropharyngeal cancers which are p16-negative are staged according to the classification for oropharynx (p16-negative) and hypopharynx cancers. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"American Joint Committee on Cancer","conceptCode":"C39315","definition":"A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"T Category","conceptCode":"C25728","definition":"One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630F8F5B-0379-7F30-E053-F662850A8A3D","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"630F8F5B-038A-7F30-E053-F662850A8A3D","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"TAYLORT","dateModified":"2018-04-09","changeDescription":"4/9/18 tt released. 1/18/18 tt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"},{"publicId":"6052641","version":"1","longName":"Oropharyngeal","context":"NCI Standards"}]},{"publicId":"6545315","version":"1","longName":"SI Workshop Query Categories","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6545446","version":"1","longName":"Pathologic Diagnosis/Stage/Grade","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Clinical T category","type":"Preferred Question Text","description":"Clinical T category","url":null,"context":"NCI Standards"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"696E1FAC-887E-0F94-E053-F662850A12FC","latestVersionIndicator":"Yes","beginDate":"2018-04-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-09","modifiedBy":"DWARZEL","dateModified":"2018-10-26","changeDescription":"4/9/18 tt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}